Outlook Therapeutics® Announces Nice Recommendation of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
- Latest
- Detail
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Latest
07:35
Zhang Jun, chief economist at Galaxy Securities, believes that the People's Bank of China is expected to take greater measures to cut interest rates and reserve requirements next year, with a potential total reduction of 40-60 basis points in the policy interest rate throughout the year, guiding the 5-year LPR down by 60-100 basis points, and a possible total reserve requirement cut of 150-250 basis points for the year.
07:29
Analyst: Currently, there is not much need for the central bank to cut interest rates again.
07:28
The chief economist of huaxi, Liu Yu, stated that the bond bull market is expected to continue in the coming year. Although there is a phenomenon of 'running ahead' in the market as the year-end approaches, it is still necessary to actively allocate cost-effective bond assets.
Huaxi-1.13%